View source for 18561468. Volumetric Next-Generation in Situ Sequencer simplified abstract (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY)

=Volumetric Next-Generation in Situ Sequencer=


==Organization Name==

[[:Category:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY|THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY]]


[[Category:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY]]

==Inventor(s)==

[[:Category:Karl A. Deisseroth of Stanford CA (US)|Karl A. Deisseroth of Stanford CA (US)]][[Category:Karl A. Deisseroth of Stanford CA (US)]]

[[:Category:Ethan B. Richman of Palo Alto CA (US)|Ethan B. Richman of Palo Alto CA (US)]][[Category:Ethan B. Richman of Palo Alto CA (US)]]

==Volumetric Next-Generation in Situ Sequencer - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18561468 titled 'Volumetric Next-Generation in Situ Sequencer

==Simplified Explanation==
This patent application describes a sequencer for automated in situ sequencing of volumetric tissue samples, including a device capable of processing multiple samples simultaneously.

* The patent application introduces an automated sequencer for in situ sequencing of tissue samples.
* The sequencer can handle volumetric samples and operate on multiple samples at once.
* Methods for fabricating and using the sequencer are also included in the patent application.

==Potential Applications==
The technology described in this patent application could have various applications in the fields of medical research, pathology, and drug development.

==Problems Solved==
This technology addresses the need for automated and efficient sequencing of volumetric tissue samples, streamlining the process and increasing throughput.

==Benefits==
The benefits of this technology include faster and more accurate sequencing of tissue samples, which can lead to improved understanding of biological processes and disease mechanisms.

==Commercial Applications==
Title: Automated Volumetric Tissue Sequencing Device for Biomedical Research
This technology could be commercially used in research laboratories, pharmaceutical companies, and diagnostic centers to enhance their sequencing capabilities and accelerate discoveries in the biomedical field.

==Questions about Automated Volumetric Tissue Sequencing Device for Biomedical Research==
1. How does this technology improve the efficiency of tissue sample sequencing?
2. What are the potential implications of using this automated sequencer in drug development research?

==Frequently Updated Research==
Stay updated on the latest advancements in automated sequencing technologies and their applications in biomedical research to further enhance the understanding and utilization of this innovative technology.


==Original Abstract Submitted==

A sequencer for automated in situ sequencing of volumetric tissue samples is provided. In particular, an automated volumetric in situ sequencing device capable of operating on multiple samples in parallel is provided. Methods of fabrication and use of the sequencer are also provided.



[[Category:G01N21/64]]
[[Category:G02B21/00]]
[[Category:CPC_G01N21/6452]]